AAN 2021 | Ubrogepant safety by age, gender and race

Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, discusses the findings of a post-hoc analysis of ubrogepant safety and tolerability across various demographic and clinical subpopulations. Ubrogepant is an oral calcitonin gene–related peptide (CGRP) receptor antagonist, known as a gepant, FDA approved for acute migraine treatment in adults. The pooled population of over 1900 patients from the ACHIEVE I and II trials (NCT02828020; NCT02867709) showed that the safety and tolerability of ubrogepant were consistent across all subgroups. Rates of adverse events were independent of age group, race, gender, BMI, and anxiety/depression medication use. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.